Sherlock Biosciences is a fast growing diagnostic company developing a portfolio of rapid point-of-need nucleic acid tests for testing at people's homes and in low-resource settings. We offer custom, co-development opportunities for additional products to leading Diagnostics and Pharma companies looking for decentralized testing solutions for diagnosis and treatment monitoring.
Our CRISPR-based engineering biology assay platform, exclusively licensed from The Broad and Harvard's Wyss Institutes, enables the detection of any genetic sequences with PCR accuracy. It is fully integrated in a simple and low-cost device platform that can take many specimen types for a wide range of potential applications from infectious disease to early detection of cancer and treatment monitoring. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.
Our CRISPR-based engineering biology assay platform, exclusively licensed from The Broad and Harvard's Wyss Institutes, enables the detection of any genetic sequences with PCR accuracy. It is fully integrated in a simple and low-cost device platform that can take many specimen types for a wide range of potential applications from infectious disease to early detection of cancer and treatment monitoring. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Diagnostics for Sexually Transmitted Infections
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
unlimited (any genetic target with SNP level detection)
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
